The Qnexa Vote: Beyond the Bean Counting
This article was originally published in RPM Report
Executive Summary
FDA's Endocrinologic & Metabolic Drugs voted 10-6 against approval of Vivus' weight loss drug Qnexa (phentermine/topiramate) at this time. But committee members were almost unanimous in agreeing that it was a very close call, and their comments captured the nuance of the many issues FDA must resolve in the context of reviewing weight loss drugs in general and this application in particular. Below is our transcript of the discussion by each panelist about the reasons for their vote.
You may also be interested in...
Setting the Stage: Qnexa and the Power of REMS
Vivus’ second trip to an advisory panel was a much happier one, with the company’s weight loss therapy garnering an overwhelming “yes” vote on approvability. The key change? A Risk Evaluation & Mitigation Strategy that will be precedent setting if approved—and that demonstrates the power of REMS even if FDA moves in a different direction with this application.
A July to Remember: Lessons from an Eventful Month at FDA
July 2010 may have been one of the busiest and most important months ever for the Food & Drug Administration's new drug regulatory group. Here are 10 themes to think about heading into the fall.
Weighing the Regulatory Climate: Qnexa and the New Approval Model
If you are looking for evidence that the regulatory climate has improved at FDA since 2007, look no farther than FDA's handling of Vivus' weight loss drug Qnexa: FDA's review team was ready to take a risk on the drug despite a number of safety signals that would most likely have killed a product three years ago. But if you want to know how fundamentally the regulatory model has changed, listen to what the committee said in rejecting the application.